Dogwood Therapeutics provides 2025 progress update

Dogwood Therapeutics Inc. (NASDAQ: DWTX) issued a corporate update detailing progress in its development of non-opioid medicines for pain and neuropathy treatment.

The biotechnology company reported recruiting over 100 patients for its Halneuron Phase 2b Chemotherapy Induced Pain study, completing an interim analysis to determine final study sample size and analysis methodology. Final Phase 2b data is projected for release in the third quarter of 2026.

Dogwood secured a royalty-free global license for SP16 IV, a potential treatment for neuropathy and inflammation caused by cancer chemotherapy. The National Cancer Institute will fully fund the upcoming SP16 Phase 1b study through a development grant.

The company advanced development of a chemically synthesized version of Halneuron to replace the current biological extract for Phase 3 development. This new formulation is expected to reduce manufacturing costs and improve yields. Dogwood filed intellectual property protection for the synthetic version, which could extend protection to 2046 if granted.

For 2026, the company plans to file an SP16 Investigational New Drug application with the FDA in the first quarter in collaboration with partner Serpin Pharma. Patient dosing in the SP16 Phase 1b study is targeted for mid-2026.

Additional milestones include executing a bridging study to compare biological and synthetic Halneuron materials and submitting end of Phase 2 summary and Phase 3 development plans to the FDA by year-end, contingent on favorable Phase 2b outcomes.

The information was provided in a letter to shareholders from CEO Greg Duncan dated January 2026.

You May Also Be Interested In

• RegenxBio completes dosing in RGX-202 confirmatory Duchenne study
• Gilat wins multi-million dollar defense SATCOM terminal order
• UMH Properties backs new manufactured housing legislation